Literature DB >> 9309994

A national estimate of the economic costs of asthma.

D H Smith1, D C Malone, K A Lawson, L J Okamoto, C Battista, W B Saunders.   

Abstract

This cost of illness analysis examines national cost and resource utilization by persons with asthma using a single, comprehensive data source, the 1987 National Medical Expenditure Survey. Direct medical expenditures included payments for ambulatory care visits, hospital outpatient services, hospital inpatient stays, emergency department visits, physician and facility payments, and prescribed medicines. Indirect medical costs included costs resulting from missed work or school and days with restricted activity at work. Point estimates and 95% confidence intervals (CI) were calculated and inflated to 1994 dollars. The total estimated cost was $5.8 billion (95% CI, $3.6 to $8 billion). The estimated direct expenditures were $5.1 billion (95% CI, $3.3 to $7.0 billion), and indirect expenditures were valued at $673 million (95% CI, $271 to $1,076 million). Hospitalization accounted for more than half of all expenditures. More than 80% of resources were used by 20% of the population (defined as 'high-cost patients'). The estimated annual per patient cost for those high-cost patients was $2,584, in contrast with $140 for the rest of the sample. Findings from this study indicate that future asthma research and intervention efforts directed at hospitalizations and high-cost patients could help to decrease health care resource use and provide cost savings.

Entities:  

Mesh:

Year:  1997        PMID: 9309994     DOI: 10.1164/ajrccm.156.3.9611072

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  88 in total

1.  Asthma outcome measures.

Authors:  K D Watkins
Journal:  J Med Syst       Date:  1999-08       Impact factor: 4.460

2.  Health information in material safety data sheets for a chemical which causes asthma.

Authors:  L M Frazier; B W Beasley; G K Sharma; A A Mohyuddin
Journal:  J Gen Intern Med       Date:  2001-02       Impact factor: 5.128

3.  Predictors of cigarette smoking and smoking cessation among adults with asthma.

Authors:  M D Eisner; E H Yelin; P P Katz; S C Shiboski; J Henke; P D Blanc
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

4.  Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population.

Authors:  L T Piecoro; M Potoski; J C Talbert; D E Doherty
Journal:  Health Serv Res       Date:  2001-06       Impact factor: 3.402

5.  Health information on the Internet: accessibility, quality, and readability in English and Spanish.

Authors:  G K Berland; M N Elliott; L S Morales; J I Algazy; R L Kravitz; M S Broder; D E Kanouse; J A Muñoz; J A Puyol; M Lara; K E Watkins; H Yang; E A McGlynn
Journal:  JAMA       Date:  2001 May 23-30       Impact factor: 56.272

6.  The influence of chronic respiratory conditions on health status and work disability.

Authors:  Mark D Eisner; Edward H Yelin; Laura Trupin; Paul D Blanc
Journal:  Am J Public Health       Date:  2002-09       Impact factor: 9.308

7.  [Concepts in studying cost effectiveness of pediatric asthma treatment in Germany, Switzerland and Austria].

Authors:  Thomas Frischer; Felix H Sennhauser; Joachim E Fischer; Thomas Szucs; Christian Köck
Journal:  Wien Med Wochenschr       Date:  2003

8.  Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema.

Authors:  Charles N Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Seth R Stevens; Diane L Whitaker-Worth; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma.

Authors:  S Suissa; P Ernst; A Kezouh
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 10.  Nasal manifestations of systemic illnesses.

Authors:  Isam Alobid; Jose Maria Guilemany; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.